Reuters logo
BRIEF-Trovagene, Nerviano announce license agreement for therapeutic candidate PCM-075
March 15, 2017 / 10:48 PM / 9 months ago

BRIEF-Trovagene, Nerviano announce license agreement for therapeutic candidate PCM-075

March 16 (Reuters) - Trovagene Inc

* Trovagene and Nerviano announce license agreement for therapeutic candidate PCM-075

* Trovagene Inc says Trovagene will assume sole responsibility for global development and commercialization of pcm-075

* Trovagene Inc- under terms of license agreement, trovagene will assume sole responsibility for global development and commercialization of pcm-075

* Trovagene inc says Nerviano will receive an upfront payment of $2.0 million, as well as development and regulatory-based milestone payments

* Trovagene Inc - co, Nerviano medical sciences signed agreement grants co exclusive global development and commercialization rights to nms-1286937

* Trovagene Inc says Nerviano will also receive royalty payments on future net sales of PCM-075

* Trovagene Inc - Trovagene plans to develop PCM-075 initially in aml Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below